| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lisuride | alpha-2a adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.09 | approved,investigational | antagonist |
| lisuride | alpha-2b adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.11 | approved,investigational | antagonist |
| lisuride | alpha-2c adrenergic receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.1 | approved,investigational | antagonist |
| lisuride | dopamine d1 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.15 | approved,investigational | antagonist |
| lisuride | dopamine d1 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.15 | approved,investigational | antagonist,agonist |
| lisuride | dopamine d2 receptor | small molecule | Successful target | TTD , drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.13 | approved,investigational | agonist |
| lisuride | dopamine d3 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.09 | approved,investigational | agonist |
| lisuride | dopamine d4 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.12 | approved,investigational | agonist |
| lisuride | dopamine d5 receptor | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.25 | approved,investigational | antagonist,agonist |
| lisuride | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.34 | approved,investigational | agonist |
| lisuride | 5-hydroxytryptamine receptor 1b | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.12 | approved,investigational | agonist |
| lisuride | 5-hydroxytryptamine receptor 1d | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.13 | approved,investigational | agonist |
| lisuride | 5-hydroxytryptamine receptor 2a | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.08 | approved,investigational | agonist |
| lisuride | 5-hydroxytryptamine receptor 2b | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.12 | approved,investigational | antagonist |
| lisuride | 5-hydroxytryptamine receptor 2c | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
0.12 | approved,investigational | agonist |
| lisuride | 5-hydroxytryptamine receptor 7 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Parkinson Disease[MeSHID:D010300] Fibrosis[MeSHID:D005355] |
NA | approved,investigational | unknown |
| click here to return to the previous page | ||||||||